Science is taking a historic step with the first human trials of messenger RNA (mRNA) cancer vaccines. These personalized vaccines have the potential to reduce cancer deaths by up to 40%, marking a new era in cancer treatment.

How do these vaccines work?
Unlike traditional vaccines, these use messenger RNA to train the immune system to identify and attack specific cancer cells in each patient. This personalized approach improves efficacy and minimizes side effects. Each vaccine is designed based on the tumor's genetic profile, allowing for a more precise attack on malignant cells without harming healthy tissue.

Potential impact
Preliminary studies show promising results, especially in aggressive cancers such as melanoma and lung cancer. These vaccines could not only reduce mortality rates but also significantly improve patients' quality of life by reducing the side effects of conventional treatments, such as chemotherapy and radiotherapy.

Challenges and future
Although developing these vaccines is costly and complex, their potential to save millions of lives makes this technology a global priority. Furthermore, it could pave the way for treating other diseases with a personalized approach. Collaboration between public and private institutions will be key to making these vaccines accessible worldwide.